Oncotarget

Research Papers:

The feasibility of 18F-AlF-NOTA-PRGD2 PET/CT for monitoring early response of Endostar antiangiogenic therapy in human nasopharyngeal carcinoma xenograft model compared with 18F-FDG

Yanfen Cui, Huanhuan Liu, Sheng Liang, Caiyuan Zhang, Weiwei Cheng, Wangxi Hai, Bing Yin and Dengbin Wang _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:27243-27254. https://doi.org/10.18632/oncotarget.8402

Metrics: PDF 2018 views  |   HTML 3007 views  |   ?  


Abstract

Yanfen Cui1,*, Huanhuan Liu1,*, Sheng Liang2, Caiyuan Zhang1, Weiwei Cheng2, Wangxi Hai3,4,5, Bing Yin1, Dengbin Wang1

1Department of Radiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

2Department of Nuclear Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

3School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China

4Med-X Research Institute, Shanghai Jiao Tong University, Shanghai 200030, China

5Med-X Ruijin Hospital Micro PET/CT Research Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

*These authors contributed equally to this work

Correspondence to:

Dengbin Wang, e-mail: [email protected]

Keywords: antiangiogenic therapy, Endostar, 18F-FDG, 18F-AlF-NOTA-PRGD2, NPC

Received: October 21, 2015     Accepted: March 14, 2016     Published: March 26, 2016

ABSTRACT

Purpose: Radiolabeled arginine-glycine-aspartic acid (RGD) peptides have been developed for PET imaging of integrin avβ3 in the tumor vasculature, leading to great potential for noninvasively evaluating tumor angiogenesis and monitoring antiangiogenic treatment. The aim of this study was to investigate a novel one-step labeled integrin-targeted tracer, 18F-AlF-NOTA-PRGD2, for PET/CT for detecting tumor angiogenesis and monitoring the early therapeutic efficacy of antiangiogenic agent Endostar in human nasopharyngeal carcinoma (NPC) xenograft model.

Experimental design and results: Mice bearing NPC underwent 18F-AlF-NOTA-PRGD2 PET/CT at baseline and after 2, 4, 7, and 14 days of consecutive treatment with Endostar or PBS, compared with 18F-FDG PET/CT. Tumors were harvested at all imaging time points for histopathological analysis with H & E and microvessel density (MVD) and integrin avβ3 immunostaining. The maximum percent injected dose per gram of body weight (%ID/gmax) tumor uptake of 18F-AlF-NOTA-PRGD2 PET/CT was significantly lower than that in the control group starting from day 2 (p < 0.01), much earlier and more accurately than that of 18F-FDG PET/CT. Moreover, a moderate linear correlation was observed between tumor MVD and the corresponding tumor uptake of 18F-AlF-NOTA-PRGD2 PET/CT (r = 0.853, p < 0.01).

Conclusions: 18F-AlF-NOTA-PRGD2 PET/CT can be used for in vivo angiogenesis imaging and monitoring early response to Endostar antiangiogenic treatment in NPC xenograft model, favoring its potential clinical translation.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8402